ProSpect Pharma has proprietary technologies enabling the interactions of molecules to be studied in high resolution - leading to improved, amended or prevented processes. Mostly the technologies have been used in the field of drug design in various collaborations including major organizations worldwide, eg Amgen Inc, Mitsubishi and NIH.
ProSpect's methods work by placing certain stable isotopes (13 C, 15 N and deuterium) in certain specific places of a molecule and examining the result by Nuclear Resonance and/or Mass Spectrometry. In this way high resolution structures and/or metabolic profiles of drug targets and their complexes can be obtained. Our methods have been shown to enable high resolution structural data to be obtained from many drug target classes, including G-Protein Coupled Receptors (GPCRs) which constitute approx 60% of all drug targets. Data from other target classes suggest that timely availability of structural information can significantly increase the efficiency of the drug design process.
ProSpect has already obtained high resolution data from 2 GPCRs and is now working with Heptares Ltd, a new company formed by a group from the LMB,Cambridge UK which recently obtained one of the first crystal structures of a GPCR. NMR experiments to expedite drug screening and design, particularly fragment-based drug design, are underway.
ProSpect's technologies are protected by issued US and European patents with further applications underway.
ProSpect has fully equipped labs for chemical and biological processes and analysis, including NMR, hplc, mass spectrometry, cell culture, protein production, etc.
